Nanalysis Sci Stock Price, News & Analysis

Nanalysis Scientific Corp. (OTCQX: NSCIF) has secured a significant five-year OEM supplier and technology licensing agreement with IMRIS Imaging, Inc., a leader in intraoperative MRI. The non-exclusive agreement includes an upfront payment and builds upon a previous 12-month contract.

The partnership leverages Nanalysis's core electronics and software technology platform, which is utilized across their benchtop NMR, high-field NMR, and MRI products. IMRIS has validated Nanalysis's MRI console during system prototyping, positioning the company as a critical component supplier for IMRIS's integrated operating suites.

Nanalysis Scientific Corp. (OTCQX: NSCIF) reported challenging Q2 2025 results marked by a 17% decline in total revenue to $9.6 million. Product sales dropped significantly by 46% to $2.9 million, while security services revenue increased by 7% to $5.6 million.

Despite revenue challenges, the company achieved notable improvements in product sales gross margins, increasing to 61% from 50% year-over-year. The company reported an Adjusted EBITDA loss of $462,000 compared to a profit of $759,000 in Q2 2024, and a net loss of $2.1 million.

Key developments include closing a $2 million promissory note financing, implementing efficiency measures in security services, and securing loan amendments to reduce principal payments through April 2026.

Nanalysis Scientific Corp. (OTCQX: NSCIF), a leader in portable NMR instruments and imaging technology, has scheduled its Q2 2025 earnings conference call for August 28th, 2025 at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will host the call to discuss results for the quarter ended June 30, 2025.

Investors can participate by dialing 1-437-900-0527 or 1-888-510-2154 from abroad, or access the webcast through the company's investor relations website. A separate European Q&A session will be held on August 29th at 8:30 AM ET. The webcast will be archived for 90 days, and a playback will be available for seven days.

Nanalysis Scientific Corp. (OTCQX: NSCIF) has achieved a significant milestone with the first regulatory certified assay for benchtop Nuclear Magnetic Resonance (NMR) being accepted by the United States Pharmacopeia (USP) and European Pharmacopeia. The certified method is for Molar Substitution Determination in Hydroxypropyl Betadex, an important excipient used in various pharmaceutical products.

This breakthrough enables the use of 60 MHz benchtop NMR for pharmaceutical quality control, marking a shift from traditional expensive and complex superconducting high-field NMR technology. The company is actively developing additional formal methods for ASTM, AOAC, and ISO standards, positioning benchtop NMR for widespread industrial adoption.

Nanalysis Scientific Corp. (NSCIF) reported Q1 2025 results with total revenue of $10.594 million, down 5% from Q1 2024. Despite macro headwinds, the company achieved positive Adjusted EBITDA of $180,000 and operating cash flows of $2.7 million. Product sales margins improved significantly to 66% from 47% year-over-year due to manufacturing efficiencies and cost-cutting measures. However, security services segment saw margin decline to 6% from 8%. Net loss improved to $1.307 million, a 48% reduction from Q1 2024's loss of $2.522 million. The company welcomed Marc Tomlinson as new EVP of Services, renegotiated its term loan facility with ATB Financial, and launched a new 60 MHz Benchtop NMR product. Management remains focused on operational excellence and improving service delivery efficiency despite potential headwinds from U.S. economic uncertainty and tariffs.

Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) has scheduled its First Quarter 2025 earnings conference call for Wednesday, May 28th, 2025, at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will discuss the financial results for the quarter ended March 31, 2025. Investors can participate by dialing 1-888-510-2154 (domestic) or 437-900-0527 (international), or via webcast.

A dedicated European Q&A session will follow on Thursday, May 29th at 8:30 AM ET. The earnings call webcast will be archived for 90 days on the company's website, and a telephonic replay will be available for seven days using conference ID #00805.

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) reported strong financial results for Q4 and full year 2024. The company achieved record quarterly revenue of $12.3 million (25% YoY growth) and record annual revenue of $45 million (60% YoY growth).

Key financial highlights include:

• Q4 Adjusted EBITDA of $1.8M vs -$677K in Q4 2023
• Annual Adjusted EBITDA of $2.8M vs -$7.9M in 2023
• Product sales gross margin improved to 53% from 41% YoY
• Security services revenue grew 121% to $21M
• Positive operating cash flow of $3.3M for 2024

The company noted potential headwinds from U.S. tariffs affecting product sales in H1 2025, though mitigation efforts are in place. Management remains focused on expanding margins, growing Benchtop NMR sales, and optimizing their service business.

Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) has scheduled its Fourth Quarter and Full Year 2024 earnings conference call for Thursday, April 24th, 2025, at 5:00 PM Eastern Time. The company will release its financial results via press release on the same day.

CEO Sean Krakiwsky and CFO Randall McRae will host the conference call. Investors can participate through:

• Dial-in numbers: 1-888-510-2154 (domestic) or 437-900-0527 (international)
• Online webcast: Available through the company's investor relations website
• Playback: Available for 7 days via phone (1-888-660-6345 or 289-819-1450, Conference ID: 87924)

Additionally, a separate Q&A session for European investors is scheduled for Friday, April 25th, 2025, at 8:30 AM ET.

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has announced the release of new automation software aimed at simplifying NMR spectroscopy for industrial applications. The qNMR module is designed to automate routine qNMR assays, making it easier for technicians to collect data without requiring expertise in NMR spectroscopy.

The software is compatible with both the company's 100 MHz and 60 MHz products, and works with autosamplers for increased throughput. This development addresses a key challenge in implementing NMR technology in quality control and quality assurance environments, where traditional NMR instrumentation has been impractical.

The company has implemented a four-pronged strategy to expand its benchtop NMR platforms in industrial QA/QC:

• Identifying and validating methods with strong ROI
• Ensuring data integrity requirements
• Exploring regulation compliance
• Reducing expertise barriers